Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study

Henzen-Logmans SC, S C Henzen-Logmans, van der Burg ME, M E van der Burg, J A Foekens, Foekens JA, Berns PM, P M Berns, R Brussée, Brussée R, Fieret JH, J H Fieret, Klijn JG, J G Klijn, S Chadha, Chadha S, C J Rodenburg, Rodenburg CJ
Journal of cancer research and clinical oncology · 1992 · vol. 118(4) , pp. 303–7 · doi:10.1007/bf01208620 · PMID:1315781 · PMC12200527
Other OA: closed
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-27 ⓘ

This immunohistochemical study of ovarian tumors and normal tissues found enhanced epidermal growth factor receptor expression in 52% of cases, with staining also present in stromal, endothelial, and necrotic areas.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-27 · read from full text ⓘ

This immunohistochemical study analyzed epidermal growth factor receptor (EGF-R) expression in 50 ovarian tumors and 10 normal ovarian tissues using monoclonal antibody 2E9. The researchers found enhanced EGF-R expression in 52% of the tumors, with staining localized to the cytoplasm of epithelial, stromal, and endothelial cells, as well as necrotic areas. Notably, no correlation existed between EGF-R levels and the histological type of epithelial tumor, while low immunoreactivity was also present in non-tumorous tissue components. These findings highlight potential confounding factors for biochemical binding studies that do not account for stromal or necrotic staining patterns. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Epidermal growth factor receptor (EGF-R) was studied with monoclonal antibody 2E9 on 50 ovarian tumors of various histological types and 10 non-tumorous ovarian tissues by immunohistochemistry. Enhanced expression was observed in 26/50 (52%) of the tumors. Only 25 out of 46 epithelial tumors (54%) showed positivity in epithelial tumor cells. Staining was cytoplasmic in all cases. No correlation was established between EGF-R expression and the histological type of the epithelial tumor. Apart from EGF-R expression in tumor cells, low immunoreactivity was also observed in stromal and endothelial cells in both normal and tumorous ovarian tissues. Furthermore in 8/9 specimens containing necrotic areas, EGF-R was noticed in these areas as well. Both of the latter observations may have impact on the evaluation of the prognostic value of EGF-R activity in tumors, when based on EGF-R measurements using biochemical binding studies. We therefore recommend that EGF-R is measured with both methods in studies regarding its clinical value.
Full text 1,889 characters · extracted from oa-html · click to expand
1992-04-01 Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study Publication Publication Journal of Cancer Research and Clinical Oncology , Volume 118 - Issue 4 p. 303- 307 Epidermal growth factor receptor (EGF-R) was studied with monoclonal antibody 2E9 on 50 ovarian tumors of various histological types and 10 non-tumorous ovarian tissues by immunohistochemistry. Enhanced expression was observed in 26/50 (52%) of the tumors. Only 25 out of 46 epithelial tumors (54%) showed positivity in epithelial tumor cells. Staining was cytoplasmic in all cases. No correlation was established between EGF-R expression and the histological type of the epithelial tumor. Apart from EGF-R expression in tumor cells, low immunoreactivity was also observed in stromal and endothelial cells in both normal and tumorous ovarian tissues. Furthermore in 8/9 specimens containing necrotic areas, EGF-R was noticed in these areas as well. Both of the latter observations may have impact on the evaluation of the prognostic value of EGF-R activity in tumors, when based on EGF-R measurements using biochemical binding studies. We therefore recommend that EGF-R is measured with both methods in studies regarding its clinical value. | Additional Metadata | | |---|---| | , , | | | doi.org/10.1007/BF01208620, hdl.handle.net/1765/62105 | | | Journal of Cancer Research and Clinical Oncology | | | Organisation | Department of Pathology | | Henzen-Logmans, S., van der Burg, M., Foekens, J., Berns, E., Brussée, R., Fieret, J., Klijn, J., Chadha, D.& Rodenburg, C. (1992). Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study. Journal of Cancer Research and Clinical Oncology, 118(4), 303–307.https://doi.org/10.1007/BF01208620 |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

ErbB Receptors Ovarian Neoplasms Ovary Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma, Mucinous Adenocarcinoma, Mucinous Adenocarcinoma, Mucinous Adenofibroma Adenofibroma Adenofibroma Adult Aged Cystadenocarcinoma Cystadenocarcinoma Cystadenocarcinoma Cystadenoma Cystadenoma Cystadenoma

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
pubmed
last seen: 2026-10-08T21:01:19.120492+00:00
unpaywall
last seen: 2026-10-10T06:25:47.132674+00:00